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Abstract
For its frequency and severity β-thalassemia represents a significant health problem
in various areas of the world. Progressive iron overload is a common complication of
hemoglobinopathies and represents a major cause of morbidity and premature
mortality in patients with β-thalassemia.The discovery of hepcidin and its role in iron
homeostasis has revolutionized our understanding of the pathogenesis of iron
overload and iron-restricted anemias, stimulating the development of new diagnostic
and therapeutic modalities for these disorders. However, little is known about the
relationship among ineffective erythropoiesis, the role of iron-regulatory genes, and
tissue iron distribution in β-thalassemia. The chapter describes evidences for these
relationships and discusses how recent discoveries on iron metabolism and erythro‐
poiesis could lead to new therapeutic approaches and better clinical care of these
diseases.
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1. Introduction
In recent years there has been important advancement in our knowledge of iron metabolism
regulation that also has implications for understanding the pathophysiology of some human
disorders such as beta-thalassemia (β-thalassemia) and other overload diseases. Progressive
iron overload has become a major cause of morbidity and premature mortality in patients with
β-thalassemia. However, little is known about the relationship among ineffective erythropoi‐
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esis, the role of iron-regulatory genes, and tissue iron distribution in β-thalassemia. Our
understanding of the pathogenesis of iron-restricted anemias and iron overload has been
revolutionized by the discovery of hepcidin and its role in iron homeostasis, stimulating the
development of new diagnostic and therapeutic modalities for these disorders. Further work
is required to understand the mechanisms of hepcidin regulation by iron and erythroid activity
and to understand the structure, the transport function and the complex regulation of the
hepcidin receptor ferroportin. The chapter describes evidences for these relationships and
discusses how recent discoveries on iron metabolism and erythropoiesis could lead to new
therapeutic approaches and better clinical care of these diseases, thereby yelding a much better
quality of life for patients suffering from iron disorders and anemias.
2. Overall view on β-thalassemia
β-thalassemias are a group of hereditary blood disorders characterized by the reduced (β⁺ or
β⁺⁺) or absent (β ⁰) synthesis of the β-globin chains of the hemoglobin (Hb) tetramer. The term
thalassemia is derived from the Greek words thalassa (sea) and haima (blood) and is one of the
most common autosomal recessive disorders worldwide. β-thalassemia is prevalent in
Mediterranean countries, the Middle East, Central Asia, Far East, as well as countries along
the Americas (Fig.1). The highest incidences are reported in Cyprus (14%), Sardinia (12%) and
South-East Asia [1‒3]. The high gene frequency of β-thalassemia in these regions is most likely
related to the selective pressure from Plasmodium falciparum malaria [1‒2]. Carriers of β-
thalassemia are indeed relatively protected against the invasion of Plasmodium falciparum.
However, because of population migration and intermarriage between different ethnic groups,
β-thalassemia is, at present, also common in Northern Europe, North and South America,the
Caribbean and Australia [4]. The inability to synthesize β-globin chains results in an excess of
α-globin chains that precipitate in red cell precursors and cause abnormal cell maturation and
their premature destruction in the bone marrow (ineffective erythropoiesis). Red cells that
survive to reach the peripheral circulation are prematurely destroyed in the spleen. The clinical
manifestations of β-thalassemia are extremely diverse, spanning a broad spectrum from the
transfusion-dependent state of thalassemia major (TM) to the asymptomatic state of hetero‐
zygous carriers for β° or β⁺ (thalassemia trait).
β-thalassemias can be classificated into:
• Thalassemia major
• Thalassemia intermedia
• Thalassemia minor
β-thalassemia with associated Hb anomalies:
• Hb C/β-thalassemia
• Hb E/β-thalassemia
• Hb S/β-thalassemia
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Hereditary persistence of fetal Hb and β-thalassemias
Autosomal dominant forms
β-thalassemia associated with other manifestations:
• β-thalassemia- tricothiodystrophy
• x-linked thrombocytopenia with thalassemia
Many different mutations cause β-thalassemia. They are inherited in a multitude of genetic
combinations responsible for a heterogeneous group of clinical syndromes. Thalassemia
minor, also known as β-thalassemia trait or heterozygous β-thalassemia, is caused by the
presence of a single β-thalassemic mutation and a normal β-globin gene on the other chromo‐
some. Microcytosis, hypochromia, increased HbA2 level and mild or minimal anemia are the
characteristic hematological features of beta-thalassemia carriers. The β-thalassemia carrier
state is clinically asymptomatic and needs no specific treatment. Thalassemia major, also
known as Cooley's anemia or homozygous β-thalassemia, is a clinically severe disorder that
results from the inheritance of two β-thalassemia alleles, one on each copy of chromosome 11.
Patients have a severe microcytic and hypochromic anemia, associated with increased number
of red blood cells and low mean corpuscular volume (MCV) and mean corpuscular Hb (MCH).
Peripheral blood smear shows, in addition to microcytosis and hypochromia, anisocytosis,
poikilocytosis and nucleated red blood cells (e.g., erythroblasts) [4]. The anemia of thalassemia
major is so severe that chronic blood transfusions are usually required. Repeated transfusions
and increased iron absorption lead to iron deposition in many organs (liver, endocrine tissues,
heart) and ultimately death unless chelation therapy is used [5]. Hemoglobin analysis shows
mainly HbF plus a small amount of HbA2 in β⁰ homozygotes, but insufficient to compensate
Figure 1. Thalassemia distribution and most common β-thalassemia mutations in different countries.
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for the loss of HbA, and the Hb level remains <5 g/dL [5]. Most β⁺ homozygotes and β⁺β⁰
compound heterozygotes also have thalassemia major. HbF remains the predominant
hemoglobin but with variable amounts of HbA depending on the specific β⁺ thalassemia allele
[5]. The term β-thalassemia intermedia (TI) is applied to a less severe clinical phenotype in
which significant anemia occurs but chronic transfusion therapy is not absolutely required.
Patients show a markedly heterogeneous hematological picture, ranging in severity from that
of the β-thalassemia carrier state to that of thalassemia major [4]. Most patients affected by
thalassemia intermedia are homozygotes or compound heterozygotes for β-thalassemia,
meaning that both β-globin loci are affected. Less commonly, only a single β-globin locus is
affected, the other being completely normal. The mild clinical characteristics of TI compared
with thalassemia major result primarily from the inheritance of two β-thalassemia mutations,
one mild and one severe; the inheritance of two mild mutations or, occasionally, the inheritance
of complex combinations, such as two β-thalassemia mutations co-inherited with heterozy‐
gous α-thalassemia. In this last form, known as αβ-thalassemia, the α-thalassemia allele
reduces the burden of unpaired α-globin chains [6‒9]. Table 1 shows some of the commonest
causes of thalassemia intermedia. The β-globin gene maps in the short arm of chromosome 11
an 80 Kb region also containing the δ globin gene, the embryonic ε gene, the fetal Aγ and Gγ
gene [4]. The five functional globin genes are arranged in the order of their developmental
expression (Fig 2) [4]. The β-globin gene is regulated by an adjacent 5’ promoter in which a
Tata, CAAT and duplicated CACC boxes are located [4]. A major regulatory region, containing
also a strong enhancer, maps 50 Kb from the β-globin gene. This locus control region (LCR)
contains four (HS-1 to HS-4) erythroid specific DNAse hypersensitive sites (HSS) containing a
variety of binding sites for erythroid transcription factors [4,10‒11]. The LCR together with the
proximal cis-element transcription factors controls the developmental stage specific expres‐
sion of genes: from ε to γ, and from γ to β and δ during development from embryo to adult.
Very early in gestation there is a switch from ε to γ-globin production. The fetal hemoglobin
(HbF) reaches a plateau after 10‒ weeks and remains high until 2‒ years after birth, when it
begins to decrease to 0.5‒1 % of total hemoglobin in adult red blood cells. The β-globin chain
synthesis starts at 30‒35‒ weeks of gestation contributing at this time to 10% of the total
hemoglobin. After birth it increases to 97 % forming the adult hemoglobin HbA. The other
type of adult hemoglobin is the HbA2 formed by δ chains whose synthesis begins at the 7 th‒
month of gestation reaching 2‒3% in adult life (Fig 2) [12]. Forms of β-thalassemia arise from
mutations that affect every step in the pathway of globin gene expression: transcription,
processing of the mRNA precursor, translation of mature mRNA, and post-translational
integrity of the β-polipeptide chain [13]. Over 200 different thalassemia alleles of the β-globin
gene have been reported; the vast majority are caused by point mutations within the gene or
its immediate flanking sequences. The distribution of alleles is highly variable from one
population to another but within each population there are only a few alleles that are common
(Fig 1) [5]. While most alleles behave as Mendelian recessives, there are variants that cause a
disease phenotype even when present in a single copy. These act in a dominant negative
fashion and are referred to as dominantly inherited β-thalassemias [5]. Conditions with HbF
production high enough to give good compensation are known as hereditary persistence of
foetal hemoglobin (HPFH) and homozygotes are clinically unaffected while compound
heterozygotes with β-thalassemia are very mild [5]. Fetal hemoglobin is a much more common
and major modifier of disease severity in individuals with β-thalassemia. In normal individ‐
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uals only 5-8% of red cells, called F cells, contains HbF,amounting to 5-20% of the total
hemoglobin in those cells [14,15]. In the context of a severe deficiency of β-globin synthesis,
even the low levels of γ-globin in F-cells reduce the relative excess of a α -globin and provide
a potent selective survival advantage for cells making HbF in the context of the ineffective
erythropoiesis characteristic of the most severe forms of β-thalassemia [14]. Some β-thalasse‐
mia mutations increase “ per se” the γ-globin gene synthesis, i.e. deletion and non deletion
δβ-thalassemia or deletions of the 5’ region of the beta-globin gene. Also mutations associated
with deletion and non-deletion HPFH linked to the β-globin gene cluster are characterized by
increasing HbF production. Recently, the genome-wide association studies (GWAS) revealed
genetic elements not linked to the β-globin gene cluster, able to modify the severity of the
homozygous β0- thalassemia. In particular, two new regulatory pathways leading to increased
γ-globin expression have been identified, i.e. BCL11A and HBS1L-MYB. Both seem to act
directly or indirectly affecting the production of repressor proteins that specifically target the
γ-globin genes [16]. The clinical phenotype of homozygous β-thalassemia may also be
modified by co-inheritance of other genetic variants mapping outside the globin clusters:. the
presence of (TA)7 polymorphism in the promoter region of the uridine diphosphate-glucuro‐
nosyltransferase gene is a risk factor for the development of cholelitiasis in thalassemia major
and intermedia patients; the apolipoprotein E ε4 allele and some HLA haplotypes, which seem
to be genetic risk factors for left ventricular failure in homozygous beta-thalassemia; a
polymorphism in glutathione-S transferase M1 gene has been associated with an increased
risk of heart iron overload in thalassemia major [1]. The expression of β-globin genes is also
affected by point mutations belonging to three different categories: mutations of promoter and
5'UTR lead to defective β-gene transcription; mutations of splice-junction and 3'UTR affect
mRNA processing; and non-sense, frameshift, and initiation codon mutations result in
abnormal mRNA translation. Phatophysiology of β-thalassemia can be summarized as
follows: the reduced amount or absence of β-globin chains result in a relative excess of
unbound α-globin chains that precipitate in erythroid precursors in the bone marrow.
Aggregation, denaturation and degradation of these chains lead to the formation of insoluble
precipitates as well as hemichromes, which damage cell membranes leading to their premature
death and hence to ineffective erythropoiesis. Red cells hemolysis within the circulation and
membrane binding of IgG and C3 causes loss of red cells in the spleen. The resulting anemia
leads to diminished tissue oxygenation, an increase in erythropoietin levels and bone marrow
stimulation and expansion causing skeletal deformities and osteopenia. Substances released
from damaged red cells increase iron absorption contributing to iron overload [14]. Diagnosis
of β-thalassemia is based on hematologic and molecular genetic testing. Differential diagnosis
is usually straightforward but may include genetic sideroblastic anemias, congenital dysery‐
thropoietic anemias and other conditions with high levels of HbF. Genetic counseling is
recommended and prenatal diagnosis may be offered. Prognosis of thalassemia minor subjects
is excellent. Individuals with thalassemia intermedia may require splenectomy, folic acid
supplementation, treatment of extramedullary erythropoietic masses and leg ulcers, preven‐
tion and therapy of thromboembolic events. Patients with thalassemia intermedia who do not
usually have severe hemosiderosis are less prone to cardiac problems [1,17]. The prognosis of
β-thalassemia major was very grim before there was any treatment available. With no
treatment, the natural history was for death by age five from infections and cachexia [1].
Treatment of thalassemia major includes regular RBC transfusions, iron chelation and
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management of secondary complications of iron overload. In some circumstances, spleen
removal may be required. However, many transfusion-dependent patients continued to
develop progressive accumulation of iron. This can lead to tissue damage and eventually
death, particularly from cardiac disease. The introduction of new iron chelators and chelation
regimes associated to the monitoring of myocardial siderosis and cardiac function have
converted a once universally fatal disease to a chronic illness. Children treated with chelators
since a very young age are expected to have an excellent long-term prognosis [18-19]. Stem
cell transplantation is at present the only available definitive cure for patients with thalassemia
major but still has a substantial risk of mortality and morbidity. Umbelical cord-blood
transplantations have had limited success in the treatment of β-thalassemia because of the
large numbers required to sustain hematopoiesis. LV-mediated gene therapy for the β-
hemoglobinopathies is now entering early-phase clinical trials and offers great promise. Even
if these approaches are successful, such molecular therapies are likely to be expensive and
might not be immediately applied to most patients in low-income countries. Much evidence
from clinical genetic studies shows that the induction of γ-globin chain synthesis by gene
transduction or pharmacological agents would have substantial clinical benefits in patients
with β-thalassemia [12,20–26]. However the results obtained have not been sufficiently
encouraging to develop large-scale trials [12,24‒26]. Furthermore, these agents have several
effects, and how any of these drugs work to increase expression of HbF is not fully understood.
Recently pre-clinical evidence of potentially new approaches to treating patients with TI and
TM has been reported. The evidence for using Tf, hepcidin agonists and JAK2 inhibitors is
discussed later in this chapter.
Figure 2. In the top panel, the organization of human β-globin locus is shown. Upstream DNase I hypersensitive sites
(HS) within the locus control region (LCR) are displayed. The bottom panel shows the fetal-to-adult hemoglobin
switch. This illustration depicts the normal timing of the developmental hemoglobin switches in humans. This figure is
adapted from [4] and [12].
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Mild deficit in β-chain production
⋅ Homozygosity for silent or mild β-thal
⋅ Compound heterozygosity for severe and mild β-thal
⋅ HbE/ β-thal
⋅ Heterozygous β-thal with ααα or αααα
Reduced α-chain excess
⋅ Homozygous β° or β+ thal with 2 or 3 α gene deletions
⋅ Homozygous β° or β+ thal with non deletion α-thal
⋅ Homozygous β+ thal with 1 or 2 α gene deletions
Increased γ-chain synthesis
⋅ Homozygous (δβ)°-thal or (Aγδβ)°-thal
⋅ Homozygosity for Hb Lepore
⋅ Compound heterozygosity for Hb Lepore/β-thal
⋅ Compound heterozygosity for severe β-thal and HPFH
Dominant β-thalassemia ⋅ Highly unstable β-chain variants⋅ Βthal heterozygotes with third exon mutations
Table 1. The commonest causes of thalassemia intermedia
3. Overall view on erythropoiesis
The production of red blood cells, known as erythropoiesis, is a developmental system
fundamentally under genetic control that involves differentiation of pluripotent hematopoietic
stem cells (HSCs) and early multipotent progenitors (MPP) in erythroblasts and mature
erythrocytes. Human erythroid differentiation is also regulated and modulated by the
interaction of humoral, cellular and molecular processes [27–30]. The erythroid progenitor cell
compartment contains the early erythroid progenitors (BFU-E, burst-forming units-erythroid),
which differentiate into late colony-forming units erythroid (CFU-E) and proerythroblasts.
BFU-E represent the earliest progenitors committed exclusively to erythroid maturation and
a quiescent reserve because only 10% to 20% are in cycle at any given time. CFU-E is more
differentiated than BFU-E and most of these progenitors (60‒80%) are already in cycle. The
earliest recognizable erythroid cells are the proerythroblasts, which differentiate in basophilic
erythroblasts, followed by polychromatophilic and orthochromatic erythroblasts. After the last
mitotic division, the inactive dense nucleus of the orthochromatic erythroblast is extruded and
the resulting mature enucleated cell is a reticulocyte. Mature red blood cells are biconcave
disks without mithocondria and other organelles, but with a very high concentration of
hemoglobin able to bind and deliver O2 [29, for an exhaustive review see 31–37]. Fig. 3
schematically represents the pathway of erythropoiesis from progenitors to mature cells. The
blood has a very important role in the functions of the organism from the earliest moments of
its development, so that during embryonic life the various stages of the hematopoietic process
alternate at different sites according to the different stages of development [38‒39]. The
embryonic →  fetal hematopoiesis is characterized by three fundamental periods of activity
progressively involving the yolk sac, liver and bone marrow. The first period, during which
hematopoiesis is localized at the yolk sac, begins between the 14th and 19th days of embryonic
life and continues until the completion of the 3rd month [38‒39]. Starting from the third month,
the second phase of hematopoiesis takes place in the liver where it reaches its maximum during
the 3rd–4th month and remains active until a few weeks before birth, when the definitive
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hematopoiesis (third phase) is concentrated only in the bone marrow and it will continue
throughout adult life [38]. In this system of hematopoietic differentiation four compartments
may be identified: stem cells, the progenitors (cellular compartments), precursors, and mature
elements of circulating blood (maturation compartments) [39]. Hematopoietic stem cells are
characterized by the ability to self-renew (i.e., to generate other totipotent stem cells) and
differentiate into hematopoietic progenitor cells. Stem cells also show the important property
to remain for a long time in a state of quiescence during adult life [36‒37,39–40]. Primitive
progenitors are able to generate blast colonies (CFU-B), the progenitors of high proliferative
potential (HPP-CFC, colony-forming cells that power high-proliferative), and finally the
multipotent progenitors that are still capable of generating mixed colonies, belonging to the
different types of hematopoietic differentiation: erythroid, granulocyte, monocyte, and
megakaryocytic (the CFU-GEMM) [37,41–42]. Mature progenitors are committed to the
differentiation towards a singular hematopoietic lineage and are functionally defined as early
burst forming units (BFUs) or more differentiated colony forming units (CFUs): erythroid
progenitors are BFU-E and CFU-E; granulocytic-macrophagic progenitors are CFU-GM, CFU-
G and CFU-M; finally megakaryocitc progenitors are BFU-Mk and CFU-Mk [37,41‒42]. The
proliferation, maturation and differentiation of hematopoietic stem cells and progenitors are
regulated by the interaction of several hematopoietic growth factors with specific membrane
receptors and the consequent activation of the appropriate signal transduction pathways.
These factors are also known as colony stimulating factors (CSFs), interleukins (ILs), or
hemopoietins and are produced from accessory cells such as macrophages, lymphocytes,
fibroblasts, and endothelial cells. They can be classified into three categories, depending on
their mechanism of action during hemopoietic differentiation (Fig.3) [34,39]. In the first
category are growth factors acting at the earliest stages of hematopoiesis, i.e. the stem cell factor
(SCF) [43], FLT-3 ligand (FL) [44,45], the basic fibroblast growth factor (bFGF) [46,47], and
interleukin-6 (IL-6) [48]. IL-3 and GM-CSF, growth factors acting as multilineage, belong to
the second category and are able to stimulate primitive progenitors to proliferate and differ‐
entiate into all hematopoietic lineage [49]. The third category includes the unilineage growth
factors acting on progenitors already committed and promoting the production of mature cells
in the circulating blood, i.e. erythropoietin (EPO) [50–51], the granulocytic growth factor (G-
CSF) [52], monocytic growth factor (M-CSF) [53], and thrombopoietin (TPO) [54]. During
hematopoietic differentiation, the maintenance of iron homeostasis is essential for erythrocytes
and macrophages. Erythroid cells need to incorporate very high amounts of iron to support
the continued synthesis of heme and hemoglobin, while the macrophage cells play a key role
in the storage and recycling of iron [29,39,55‒56]. During the differentiation of erythroid
progenitors towards mature red cells the following morphologically recognizable stages can
be distinguished: 1) the earlier stage of proerythroblast, that presents a nucleus relatively large
in respect to the cytoplasm, and one or two nucleoli; 2) the more advanced basophilic eryth‐
roblast, characterized by a reduced cellular diameter, a nuclear volume reduced more rapidly
than the cytoplasm, and a cytoplasm uniformly basophilic; 3) the polychromatophilic eryth‐
roblast, that shows the initial condensation of the nucleus, nucleoli no longer visible and the
cytoplasm with acidophilic areas; 4) the orthochromatic erythroblast, with a nucleus:cyto‐
plasm ratio of approximately 1:4, nucleus darker and subject to pyknotic degeneration, and
cytoplasm slightly pink as a consequence of the progressive increase in hemoglobin concen‐
tration; and finally 5) the reticulocyte that has lost its nucleus and, through the complete
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degradation of ribosomes and mitochondria, proceeds to the transformation in mature
erythrocyte [34,37,39,42,57–58]. In adult mammalian bone marrow erythroblasts are always
associated with the erythroblastic islets that represent the drive amplification stage anatomy
of erythropoiesis and consists of 1 or 2 histiocytic crown cells surrounded by erythroblasts at
all stages of maturation. The histiocytes have thin cytoplasmic extensions that insert between
erythroblasts suggesting that factors of nutrition can be provided by the histiocytic cell,
centrally located, to the peripheral maturing erythroblasts [37,39,42]. The most important
factor involved in the control of erythropoiesis is erythropoietin, but other substances,
particularly hormones, contribute to the regulation of this process [59]. Transferrin comes out
from the bone marrow sinusoids using ample fenestrature exits, and binds to surface receptors
carried by erythroblasts. The iron transferred from transferrin and transported to the mito‐
chondria is reduced from Fe3+ to Fe2+ and then inserted into protoporphyrin IX by tetrapyr‐
roles heme synthetase (Heme Synthetase HS) for the synthesis of heme [39,55‒56,59]. The
reticuloendothelial system is a functional unit that includes cells having heterogeneous
histologically different identities and a widespread distribution throughout the body, which
share the common property of phagocytic activity, e.g. endothelial cells of blood capillaries of
liver, spleen, bone marrow and lymph-nodes, tissue and circulating macrophages [59–60].The
reticuloendothelial system is the most important source of iron that enters the blood compart‐
ment. The flow of iron from the reticuloendothelial plasma is unidirectional, as the reticu‐
loendothelial cells are not able to pick up the metal from transferrin, but receive only
hemoglobin or ferritin iron [59‒60]. Senescent erythrocytes at the end of their life (approxi‐
mately 120–days) are phagocytized by endothelial cells and represent the largest source of iron
entering the reticuloendothelial system. About 85% of the iron that enters the reticuloendo‐
thelial cells is promptly transferred to plasma transferrin and the remaining 15% is stored as
intracellular ferritin, and transferred to plasma much more slowly [39,42,59‒60]. The produc‐
tion of red blood cells is regulated by a complex network of transcription factors, among which
GATA-1 is considered the master gene of erythropoiesis. GATA-1 positively regulates specific
erythroid genes such as erythropoietin receptor (EpoR), glycophorin (GpA), and globin chains
and, together with the transcription factor STAT5, induces the expression of the antiapoptotic
protein Bcl-xL (Fig.3 and Table 2) [61–63]. The program of erythroid proliferation and differ‐
entiation must be positively and negatively regulated to ensure a continuous but tightly
controlled production of red blood cells. Erythropoiesis is positively controlled by the
combined effect of two major cytokinesis, SCF and Epo. SCF is produced by stromal cells and
exerts its effects on erythroid cells mainly during the early and late stages of differentiation of
erythroid progenitors, and may act also on immature erythroid precursors. Epo is responsible
for the finely tuned homeostatic control of erythrocyte numbers by tissue oxygenation. Epo
exerts its effect by stimulating Epo-R. The binding of Epo with the EpoR induces a conforma‐
tional change that activates the pre-bound, cytoplasmic tyrosine kinase JAK2. The activation
of JAK2 induces multiple signaling pathways involving P13 kinase, Akt and STAT5, which
prevent apoptosis, supporting erythroid progenitors proliferation and differentiation (Fig.3)
[63‒66]. However, a negative control of erythropoiesis is clearly required at several levels to
avoid overproduction of erythroid cells and polycythemia, which may lead to hyperviscosity
and ultimately to thrombosis. The negative regulation is mainly due to apoptosis, a funda‐
mental cellular mechanism allowing clearance of unneeded or potentially dangerous cells.
Caspases appear to play a critical role in erythroid apoptotic programs. Caspases belong to a
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family of cysteine-dependent and aspartate-specific proteases and, in particular, two classes
are described: initiators (caspase-8 and –9) and effectors (caspase-3 and ‒7). Caspase-8 is
activated by the death receptor pathway and caspase-9 by events causing intracellular
damages and alterations in mitochondrial membrane potential. Activated caspase –8 and
caspase ‒9 then activate effectors such as caspase –3 that cleaves GATA-1, Tal-1, and proteins
involved in cytoplasm, nucleus, and DNA integrity, which allow the cell death program to
occur. Death receptors of the TNF receptor (TNF-R) superfamilies (Fas-L, TNF-α, TRAIL)
activate the extrinsic apoptotic pathway. Some studies suggest the existence of a negative
regulatory feedback operating at low Epo level in a paracrine pathway. Briefly the control of
mature red blood cell production may be summarized as follow: at low doses of Epo, cells die
by apoptosis, at intermediate doses, cells are arrested in their maturation or enter a program
of apoptosis, depending on the number of mature erythroblasts in the bone marrow, and at
high doses of Epo, erythroid progenitors and precursors pursue their maturation independ‐
ently of the number of mature erythroid precursors [63,67‒68]. In summary, the emerging
picture is that certain genes, such as SCL, are absolutely required for hematopoietic develop‐
ment, whereas others, such as GATA- 2, c-Myb, CBF and some downstream signal transducing
molecules, such as Jack 2 and STAT5, are responsible for expansion and maintenance of a
normal pool of fetal liver and adult hematopoietic progenitors. The participation of many of
these molecules in multicomponent molecular complexes with protein/protein and
protein/DNA interactions (e.g., LMO2/Lmbd1/SCL/GATA), during the early, proliferative
stages of hematopoiesis may underlie their role in the proliferation and maintenance of
immature progenitor/precursor pools in erythropoiesis [69]. Other genes such as GATA1, its
partner FOG1, and EKLF are necessary to direct high levels of function of erythroid-specific
genes in cells already committed to terminal differentiation. Thus, a hierarchical requirement
in the expression of specific regulators during early versus late erythroid differentiation or
during embryonic versus fetal liver/adult erythropoiesis is established.
Figure 3. A) Pathway of the erythropoiesis from progenitors to mature cells. Different stages are indicated: hemato‐
poietic stem cell (HSC), burst-forming unit erythroid (BFU-E), colony-forming unit erythroid (CFU-E), proerythroblast
(ProE), basophylic (BasoE), polychromatic (PolyE), and orthochromatic erythroblast (OrthoE). B) Erythroid transcrip‐
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tion factors: basic helix-loop-helix factor (TAL1); Lim-domain partner of TAL1 (LMO2); zinc finger factors that bind
GATA sequences (GATA-1, GATA-2); GATA-1 partner, friend of GATA (FOG); erythroid Kruppel-like factor (EKLF)
and p45NF-E2 (NF-E2). C) Receptors for hematopoietic growth factors: stem cell factor-receptor/c-kit; erythropoietin
receptor (EPO-R) and insulin-like growth factor-1 receptor (IGF-1-R). D) Proteins related to erythrocyte structure and
function. Modified by [39] and [32].
Trans-acting
factor
Binding motif Role in
hematopoiesis
Target genes Phenotype of gene
inactivation
Human pathology
GATA-1 (A/T) GATA
(A/G)
↑  Erythroid
differentiation
Globin, erithroid,
specific membrane
proteins, GATA-1,
GATA-2
Anemia and
trombocytopenia
X-linked thalassemia/
trombocytopenia
GATA-2 (A/T) GATA
(A/G)
↑  Proliferation
↓  Differentiation
GATA-1, GATA-2 No proliferation of
immature
progenitors
FOG-1 None GATA-1-cofactor No erythroid
maturation
EKLF CACC Promotes terminal
erythroid
differentiation
Globin Anaemia β-thalassemia
SCL CANNTG (E box) Specification of
hematopoiesis
Absence of prenatal
hematopoiesis
Translocation in T-
ALL
LM02 Lim domain Absence of
hematopoiesis
T-CELL acute
lymphocytic leukemia
Myb (T/C) AAC (G/T)
G
↓  Definitive
erythropoiesis
Block in definitive
erythropoiesis
STAT 5 GAS Antiapoptotic effect
at level of erythroid
precursors
BCL-XL Anemia due to
apoptosis of
erythroid progenitors
NFE 2 TGAGTCA Promotes terminal
erythroid
differentiation in
vitro
Enzyme of the
haem biosynthetic
pathway,globin
trombocytopenia
Table 2. Major transcription factors/signaling molecules involved in the control of erythropoiesis. DNA-binding sites
and known target genes of the indicated transcription factors together with the phenotype of their gene inactivation in
mice and the human pathologies associated with gene mutations are shown.
4. Iron metabolism and erythropoiesis
Iron plays a pivotal role in cell survival and proliferation by regulating enzymatic activity and
oxidation-reduction reactions. It is essential primarily for ensuring the transport of oxygen and
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for the catalysis of reactions involved in electron transfer, nitrogen fixation and DNA synthe‐
sis, but it is also toxic due to its capacity to react with oxygen and catalyze the production of
reactive oxygen species. In solution, iron can exist in two states of oxidation, Fe (II) and Fe (III),
and is very poorly soluble at physiological pH, especially when it is in the oxidized form Fe (III).
Living organisms have thus developed many proteins to carry iron in biological fluids and
transport it through cellular membranes, and to store it in a non-toxic and easily mobilizable
form [70‒72]. Erythropoiesis and iron metabolism are processes closely linked to each other.
The large majority of iron in our body is utilized by the erythropoietic system to generate
functionally active hemoglobin molecules, which are harbored in the red blood cells. It is
estimated that 1800 mg of iron in our body is present in red blood cells, 300 mg in the bone
marrow and 600 mg in the reticuloendothelial macrophages of the spleen [71], accounting for
more than 60% of total body iron. Approximately 10% is present in muscle fibers (in myoglo‐
bin) and other tissues (in enzymes and cytochromes) and the remaining body iron is stored in
the liver. The normal diet contains 15‒20 mg of iron, and the body absorbs 1–2 mg/d of dietary
iron. This is balanced with losses via sloughed intestinal mucosal cells, menstruation and other
blood losses. Therefore, internal turnover of iron is essential to meet the bone marrow require‐
ments for erythropoiesis (20–30 mg/d) (Fig. 4) [73–75]. This massive utilization of iron by the
erythropoietic system requires the presence of finely tuned regulatory systems that allow
storage, mobilization and traffic of iron and at the same time prevent toxicity due to highly
reactive iron ions. Because there are no physiologically regulated means of iron excretion, dietary
iron absorption is highly regulated primarily at the level of duodenal enterocytes. Other
important regulatory sites are the liver and the spleen. Hepatocytes and Kuppfer cells can store
large quantities of iron, while iron from senescent red blood cells is recycled from macrophag‐
es in the spleen. All three compartments are of pivotal importance for erythropoiesis since they
control the bioavailability of iron to erythroid progenitors, and all of them respond to hepci‐
din, the master regulator of iron metabolism [76]. A summary of proteins involved in iron
homeostasis, as well as their most frequently used acronyms, is given in Table 3 and Table 4.
Transferrin is the main plasma iron transporter that binds two molecules of ferric iron (Fe3+).
At the systemic level, transferrin satuaration is the main iron sensor and plays a role in controlling
the levels of the iron-regulatory peptide hepcidin [77]. Transferrin is usually between 20 and
30% satured with iron. At the cellular level we known two common mechanisms that can be
applied to most of the proteins involved in iron metabolism regulation. First, iron- regulatory
proteins 1 (IRP1) and 2 (IRP2) bind to iron-response elements (IREs) in the untranslated regions
(UTRs) of mRNA encoding protein involved in cellular iron uptake, storage, and export. IRP1
and IRP2 bind to IREs under conditions of low iron, and they dissociate from IREs in high-
iron states [77–78]. If the IRE is in 3'UTR, IRP binding stabilizes the mRNA, prevents degrada‐
tion, and increases protein production. If the IRE is in the 5'UTR, mRNA translation is inihibited.
There are over 35 mRNAs, including hypoxia-inducible factor 2α, that have an IRE and are
responsive to iron. The second general mechanism imparts tissue-specific sensitivity to iron
balance by modulation of the proportion of iron-sensitive and iron-insensitive mRNAs. This
means that one variant responds to iron levels and one does not. The ratio of IRE to non-IRE
differs in different tissues, resulting in differences in responsiveness to iron and differences in
loading [77]. In specialized cell types, alternatively spliced non-IRE-containing isoforms of
ferroportin [34] and DMT1 [79] mRNAs bypass post-transcriptional regulation by IRPs. Under
normal circumstances, dietary ferric iron is reduced by cytochrome B to ferrous iron (Fe 2+) at
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the apical brush border of duodenal enterocytes and transported into the cell by DMT1. DMT1
expression is highest at the duodenum and decreases towards the colon. Dietary heme iron is
absorbed into the enterocyte via the heme carrier protein-1 Inside the enterocyte, heme is
degraded by heme oxygenase and iron is released into the cytosol. The free iron is stored in the
cells by ferritin or exported to the plasma by FPN1 [77,80–81]. Exported iron is loaded onto
transferrin. Before the loading of transferrin, ferrous iron is oxidized to Fe 3+ by hephaestin.
Cells can then take up transferrin-bound iron via transferrin receptor 1 (Tfr1, aka CD71).
Erythroblasts, the major iron consuming cells in the organism, mainly take up transferrin-
bound iron via transferrin receptor 1 (TfR1). Iron release takes place in vesicles of low pH. Ferric
iron is reduced to ferrous iron by Steap3 and subsequently exported into the cytosol via DMT1,
while transferrin and TfR1 recycle to the surface. The bulk of intracellular iron in erythro‐
blasts is used for hemoglobin synthesis,  where mitochondria are indispensable for heme
production. Excess heme is either exported via FLVCR or catabolized via the HO-1 pathway
[39,82]. As the intake of nutritional iron is not sufficient to cover the daily iron necessity of
erythropoiesis, iron recycling is necessary. Macrophages exert a crucial role in iron recycling,
phagocytosing senescent erythrocytes, and releasing accumulated iron back into the circula‐
tion in a regulated manner, thus enabling iron recycling [82]. Phagocytosed erythrocytes are
broken up in lysosomes, and heme-bound iron is released via HO-1. When body iron levels are
low, storage iron re-enters the circulation. Ferroportin again functions as the only known iron
exporter, and another plasma copper-containing ferroxidase coeruloplasmina converts ferrous
into ferric iron before its loading onto transferrin [82]. Similar to reticuloendothelial cells,
hepatocytes are an important site of iron storage in the form of ferritin. Most important,
hepatocytes serve a central role in iron homeostasis as the site of regulated production of the
hormone hepcidin. Hepcidin functions as the “hypoferremia hormone” by down-regulating
the ferroportin-mediated release of iron into the circulation [83]. The consequent iron reten‐
tion in duodenal enterocytes decreases dietary iron absorption and the iron retention in
reticuloendothelial macrophages decreases iron turnover. Hepatocellular hepcidin produc‐
tion is regulated by signals reflecting inflammation, iron status, erythropoietic activity, and
oxygen tension [83]. Major pathways of iron traffic between cells and tissues are indicated in
Fig. 4.
Figure 4. Major pathways of iron traffic between cells and tissues.
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Protein name Acronyms Funcion in iron metabolism Localization
Iron aquisition
Transferrin Tf Plasma iron transfer Plasma
Transferrin receptor 1 TfR1 Internalization of holo-Tf Ubiquitously expressed
Six transmembrane
epithelial antigen
of the prostate 3
STEAP3 Ferric reductase in the endosomes of
erythroid cells
erythroblast
Divalent metal
transporter 1
DMT1 Epithelial/endosomal transport
of ferrous iron
Enterocyte (apical membrane)
Duodenal cytochrome b Dcytb Apical membrane ferric
reductase of enterocytes
Enterocyte (apical membrane)
Heme oxygenase 1 HO-1 Degradation of hemoglobin
for Fe2+ release
Enterocyte
Ferritin Ft Cellular iron storage and uptake Enterocyte, erythroblast ,
macrophage, hepatocyte,
myocytes and cardiomyocytes
Intracellular iron transport
Mitoferrin 1/2 MFRN 1/2 Import of ferrous iron to
mitochondria
Erythroblast (mitochondria)
Iron efflux
Ferroportin FPN1 Export of ferrous iron Enterocyte (basolateral membrane)
Macrophages, hepatocytes,
Erythroid cells
Hephaestin HEPH Membrane-bound ferroxidase Enterocyte (basolateral)
Ceruloplasmin CP Plasma ferroxidase macrophage
Feline leukemia virus,
subgroup C, receptor
FLVCR Heme export Erythroblast
Table 3. Main proteins involved in iron homeostasis
PROTEIN NAME
Systemic iron
metabolism
Acronyms Function Phenotype due to loss of function
Hepcidin HEPC Inhibition of ferroportin
mediated efflux
Absent hepcidin expression. Iron
overload at the level of liver and
pancreas and at a lesser extent
of heart (HH type2A)
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PROTEIN NAME
Systemic iron
metabolism
Acronyms Function Phenotype due to loss of function
Bone morphogenetic
protein 6
BMP6 Regulation of hepcidin
expression in response to
hepatic iron
Iron overload with decreased
levels of hepcidin
Hemojuvelin HJV Enhancement of BMP signaling
to hepcidin
Early onset severe iron overload
with suppressed hepcidin expression
(HH type2A)
Transferrin Tf Plasma iron transfer Iron deficiency anemia with tissue iron
overload
High Fe protein HFE Regulation of hepcidin
expression by plasma iron
Iron overload with decreased levels
of hepcidin (HH type 1)
Transferrin receptor 2 TfR2 Regulation of hepcidin
expression by plasma iron
Iron overload with decreased levels of
hepcidin (HH type 3)
SMAD 4 SMAD4 Signaling to hepcidin Decreased hepcidin levels and iron overload
Matriptase-2 TMPRSS6 Proteolytic cleavage of Hjv Macrocytic anemia with low iron
stores and increased hepcidin
Neogenin NEO Regulation of Hjv Hepatic iron overload
Cellular iron
metabolism
Iron regulatory protein 1 IRP 1 Post-transcriptional regulation
of IRE-containing mRNAs
Not known
Iron regulatory protein 2 IRP 2 Post-transcriptional regulation
of IRE-containing mRNAs
Misregulation of iron metabolism.
Neurodegenerative disease due to
iron accumulation in neurons and
oligodendrocytes
F-box and leucine-
rich repeat protein 5
FBXL 5 Iron-dependent ubiquitination
and degradation of IRP 2
Embryonic lethality
Table 4. Main proteins involved in iron homeostasis regulation
5. Hepcidin: The link between erythropoiesis and iron regulation
In recent years, there has been important advancement in our understanding of iron metabo‐
lism, mainly as a result of the discovery of hepcidin, a key regulator of whole body iron
homeostasis originally identified from urine as an antimicrobial peptide produced in the
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hepatocytes [84]. The aim of this chapter is beyond a complete picture of current knowledge
on the hepcidin regulation, therefore I will focus only on those aspects that influence erythro‐
poiesis directly or indirectly. Targeted deletion of the HAMP gene in mice or mutations in the
human HAMP gene result in massive iron overload [85]. Conversely, high levels of hepcidin
lead to decreased iron absorption and iron-restricted anemias. Therefore, hepcidin is a negative
regulator of iron transport into plasma. Experimental data suggested that the hepcidin could
be the regulator of iron absorption and recycling acting principally or solely by binding to
ferroportin, the only known cellular iron exporter. The hepcidin-ferroportin interaction
controls systemic iron homeostasis: hepcidin binds to ferroportin and induces its internaliza‐
tion and degradation. This mechanism regulates the distribution of iron in the body. When
hepcidin levels are low, iron-exporting cells, including duodenal enterocytes, macrophages,
and hepatocytes display abundant ferroportin and release iron into plasma. When hepcidin
concentration increase, hepcidin binds to ferroportin, causing its phosphorylation, internali‐
zation, ubiquitylation, sorting through the multivesicular body pathway, and degradation in
lysosomes, and iron is retained within cells in cytoplasmic ferritin [34,82,86–89]. Hepcidin is
regulated at transcriptional level by different stimuli that can act as positive or negative
regulators. The membrane isoform of hemojuvelin (HJV), transferrin receptor 2 (TfR2), IL-6,
iron and the hemochromatosis protein HFE are all positive regulators of hepcidin transcrip‐
tion. On the contrary, hypoxia, anemia, iron deficiency, and erythroid expansion are all
negative regulators of hepcidin expression. We know four major regulatory pathways that act
through different signaling pathways to control the transcription of hepcidin, e.g. iron
erythroid demand, hypoxia, iron store, and inflammation. Briefly, hepcidin transcription is
activated by BMP-6 (Bone morphogenetic protein 6) via the SMAD pathway. Hemojuvelin
(HJV) enhances the activity of the BMP receptor (BMP-R), while cleavage of HJV by TMPRSS6
suppresses this activity. Diferric Tf displaces the hemochromatosis protein (HFE) from the
high-affinity transferrin receptor (TfR1) that associates with TfR2 enhancing signaling via
BMP-R. Inflammatory cytokine IL-6 acts through its receptor (IL6-R) and the JAK2/STAT3
pathway to turn on hepcidin production. Growth differentiation factor 15 (GDF15), twisted
gastrulation-1, erythroferrone (ERFE), hypoxia, and erythropoietin (Epo) reduce hepcidin
transcription [89–93]. GDF15 is released by erythroid precursors and increased in hemoglobi‐
nopathies, e.g. thalassemia, congenital dyserythropoietic anemia type 1, and refractory anemia
with ring sideroblasts. GDF15 is decreased post transfusion, in parallel with EPO and de‐
creased marrow activity, resulting in increase in hepcidin. Twisted gastrulation (TWSG1),
soluble HJV, and erythroferrone (ERFE) are other factors that are rapidly produced with
increased erythroid activity and result in reduced hepcidin production. ERFE belongs to the
C1q-tumor necrosis factor-related family of proteins. In response to EPO, ERFE is rapidly
produced by erythroid precursors in the bone marrow and the spleen via signal transducer
and activator of transcription 5 (STAT5). The canonical Janus kinase 2 (Jak2)/Stat5 signaling
pathway is a known mediator of EPO response and stress erythropoiesis. Further work is
necessary to confirm whether ERFE is the long-sought erythroid regulator responsible for
hepcidin suppression and iron overload in patients with hereditary iron- loading anemia [92,
94–97]. Regulation of hepcidin production is shown in Fig.5
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Figure 5. Iron-mediated regulation of hepcidin levels on hepatocytes.
6. Ineffective erythropoiesis and iron overload in β-thalassemia
In β-thalassemia the erythropoietic process is markedly altered and is referred to as ineffective
erythropoiesis (IE). The lack or reduced synthesis of β-globin chains induces an excess of free
α-globin chains within erythroid cells. Aggregation, denaturation, and degradation of these
chains leads to the formation of insoluble precipitates that cause oxidative membrane damage
within the red blood cell and developing erythroblasts [98]. In β-thalassemia the process of IE
is accompanied by a massive iron overload, due to an increased rate of iron absorption by the
gastrointestinal (GI) tract and to frequent blood transfusions. Nevertheless, iron overload
occurs also in patients who have not received transfusions such as patients suffering from
thalassemia intermedia [63,99]. In patients who are iron- overloaded, the capacity of serum
transferrin to bind iron may be exceeded, which means that a non-transferrin-bound fraction
of iron may circulate in the plasma. This unbound iron, which is carried in the iron storage
protein ferritin, can promote the generation of free hydroxyl radicals, which propagate oxygen-
related tissue damage. Additionally, insoluble iron complexes called hemosiderins may
become deposited in body tissues causing toxicity and death. Cardiac failure is a major
complication of iron overload. Iron deposition can cause myocarditis and cardiac fibrosis.
There are a number of other possible complications of iron overload: excess iron deposition in
the liver can lead to fibrosis/cirrhosis or cancer, and diabetes mellitus may occur as a result of
beta-cell destruction secondary to iron overload in the pancreas. Excess iron overload in the
pituitary may cause growth failure due to hypogonadism and infertility due to reduced
gonadotropin levels [86,100–101]. If iron were a dominant regulator, patients with β-thalasse‐
mia should express very high levels of hepcidin in serum in order to decrease intestinal iron
absorption. In contrast, the levels of hepcidin are very low in these patients, suggesting that
the ineffective erythropoiesis alone is able to suppress the synthesis of hepcidin in spite of the
presence of a severe iron overload [89,102–104]. Hepcidin deficiency develops as a result of a
suppressive signal generated by the greatly expanded erythroid precursor population. This
also leads to excessive iron absorption and the development of iron overload even in patients
who are not transfused. Although the hepcidin suppression is partially relieved by erythrocyte
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transfusions, the transfusions themselves add large amounts of exogenous iron again leading
to iron overload. The observation that serum from β-thalassemic patients inhibited hepcidin
mRNA expression in the HepG2 cell line suggested the existence of a negative erythropoietic
regulator of hepcidin expression [105]. The nature of this humoral factor is still uncharacter‐
ized, but may include one or more proteins during active erythropoiesis. One of this regulators
could be the cytokine growth differentiation factor-15 (GDF15) because it was observed that
serum from thalassemia patients suppressed hepcidin mRNA expression in primary human
hepatocytes and depletion of GDF15 reversed the hepcidin expression. GDF15 is a divergent
member of the transforming growth factor-beta superfamily that is secreted by erythroid
precursors and other tissues. It has been identified as an oxygen-regulated transcript respond‐
ing to hypoxia and as a molecule involved in hepcidin regulation. It was suggested that GDF15
overexpression arising from an expanded erythroid compartment contributed to iron overload
in thalassemia syndromes by inhibiting hepcidin expression, possibly by antagonizing the
BMP pathway [89,93]. GDF15 mRNA levels and secreted protein were up-regulated in
response to iron depletion in a range of human cell lines and “in vivo” in humans and this up-
regulation was independent of HIF suggesting the existence of a novel iron and oxygen-
sensing pathway [106]. Finally, the observation that GDF15 was induced by over-expression
of wild type ferroportin connects the iron-mediated regulation of GDF15 concentration to
patho-physiological levels of iron. Despite systemic iron overload, ineffective erythropoiesis
and associated iron-fluxes in beta-thalassemia might generate an iron deficiency signal in a
relevant molecular or cellular context and consequent stimulation of GDF15 expression in a
particular erythroid compartment [106]. Experimental data provided the evidence that TWSG1
could be potentially involved in the regulation of hepcidin by erythropoiesis. In contrast to
GDF15, the expression of human twisted gastrulation factor (TWSG1) occurs early during
erythroblast maturation before hemoglobinization of the cells. TWSG1 is another highly
expressed serum protein in thalassemia suppressing hepcidin transcription by interfering with
BMP signaling either directly, by acting on BMP receptors, or indirectly by influencing
circulating BMP2 and BMP4 levels. So it was proposed that TWSG1 might act with GDF15 to
dysregulate iron homeostasis in β-thalassemia [107]. Results obtained by HuH7 hepatoma cells
cocultered with primary human erythroblasts or erythroleukemic UT7 cells presented a 20- to
35-fold increase of hepcidin expression and identified OsM responsible for this increase of
hepcidin levels. In contrast to GDF15 and TWSG1, it was showed that OsM could induce
hepcidin transcription in human hepatoma cell lines mainly through the JAK/STAT pathways
[108–109].
7. New therapeutic approaches to limit iron absorption in β-thalassemia
For its frequency and severity β-thalassemia represents a significant health problem in various
areas of the world. Conventional treatment of thalassemia includes transfusion therapy, iron
chelation therapy and, in rare cases, splenectomy. Regular blood transfusions in combination
with aggressive iron chelation have been remarkably effective in delaying the onset of iron-
related organ failure and improving mortality but, in spite of this, many patients continue to
be affected by cardiac disease and other clinical complications, e.g. develop endocrine failure
and delayed pubertal maturation. To add that this rigorous life-long treatment regime is
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onerous and represents an enormous imposition on quality of life. Allogeneic hemopoietic
stem cell transplantation is the only approach that may lead to a definitive cure but it is not
available to most patients. The understanding of β-thalassemia pathophysiology has involved
more than 50 years of biochemical and biological studies leading to the development of
alternative therapies to cure or ameliorate the disease. New potential molecular targets for β-
thalassemic therapy can be divided into three categories. To the first category belong the
primary targets that include all of the molecular defects that lead to a decrease in β-globin
synthesis. Hemopoietic stem cell transplantation (HSCT), gene therapy using viral vectors and
antisense mRNA are an example of strategies targeting the primary causes of reduced β-globin
expression. To the second category belong the secondary targets including modifiers of chain
imbalance in β-thalassemia by increasing of γ-globin synthesis. Gene therapy approaches for
the induction of HbF synthesis include transduction of lentiviral vectors incorporating γ-
globin/β-LCR, or attemps to promote endogenous gamma-globin expression using artificial
transcription factors. Pharmacological approaches for the induction of gamma-synthesis
include the treatment with erythropoietin (EPO) preparations, or short chain fatty acid
derivatives (SCFADs) or chemotherapeutic agents as hydroxycarbamide (HU) and 5-azacyti‐
dine. To the third category belong the tertiary targets that are those directed at treating the
complications of β-thalassemia such as iron overloading and oxidative cellular damage [23–
25,89]. In recent years increasing experimental evidences indicated that there was a potential
for therapeutic intervention in β-thalassemia by means of manipulating iron metabolism [110–
113]. In mice that completely lack Stat5 activity, it was observed that cell surface levels of TfR1
on erythroid cells were decreased more than 2-fold suggesting a link between EpoR/Jak/Stat
signaling and iron metabolism [114]. Another study suggested a direct involvement of Epo in
hepcidin regulation through the transcriptional factor C/EBP alpha [115]. It was also observed
a link between Jak2 and FPN1: Jak2 phosphorylates FPN1 following its binding to hepcidin
triggering its internalization and degradation [116]. Therefore, Jack2 might represent one of
the major links at the interface between erythropoiesis and iron metabolism suggesting that
use of Jak2 inhibitors, antioxidant, and analog of the hepcidin might reduce ineffective
erythropoiesis and abnormal iron absorption. Several JAK2 inhibitors have already been
developed, showing significant and beneficial results in myelofibrosis and JAK2-related
polycythemia vera [117]. However, trials with JAK2 inhibitors in myeloproliferative disorders
have also shown several side effects, among them thrombocytopenia and anemia. On the
contrary, in preclinical thalassemic models, splenomegaly was reversed in less than two weeks
and no side effects were observed [117]. Administration of synthetic hepcidin or of agents that
increase its expression, may be beneficial in controlling absorption of this metal. Hepcidin
agonists or stimulators of hepcidin production are being developed for the treatment or
prevention of iron overload in hepcidin deficiency states, including hereditary hemochroma‐
tosis and β-thalassemia. It was observed that transgenic hepcidin therapy improved iron
overload as well as erythropoiesis in the mouse model of β-thalassemia [118]. The rationale
for the use of hepcidin agonists is justified by two principal observations: first, the phlebotomy
is an inexpensive and effective treatment for iron overload that is acceptable to must but not
all patients affected by hereditary hemochromatosis; second, the iron-loading anemias cannot
be treated in this manner and require iron chelation therapy, which is not well tolerated by
many patients. Hepcidin agonists are agents that replace hepcidin activity or stimulate its
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endogenous production and, in both of hereditary hemochromatosis and iron-loading
anemias, could prevent iron accumulation by redistributing iron from parenchymal tissues to
macrophages where iron is less toxic. Results obtained treating a mouse model of β-thalasse‐
mia with hepcidin agonists suggested that the use of these agents could not only prevent iron
overload but could also improve erythropoiesis, perhaps by decreasing excessive alpha-globin
synthesis or diminishing oxidative stress in erythropoietic precursors [119–120]. Minihepci‐
dins are short peptide mimetics (9AA long) that are sufficient to induce FPN1 degradation in
reporter cells. The extracellular loop of ferroportin surrounding the thiol cysteine C326 appears
to be essential for hepcidin binding, as indicated by the lack of hepcidin binding to otherwise
fully functional ferroportin containing the isosteric mutation C3265 [119]. Analysis of the
interface between hepcidin and ferroportin showed that the segment composed of a 9 N-
terminal amino acid segment of hepcidin is sufficient for binding and internalization of
ferroportin [121]. These small modified mini-hepcidin peptides show bioactivity in vivo, as
determined by their ability to induce hypoferremia in mice and to prevent iron accumulation
in hepcidin-deficient mice [119]. Potential drug target also is the transmembrane protease
serine 6 (TMPRSS6) or Matriptase-2, a transmembrane serine protease that attenuates hepcidin
expression. The fundamental role of TMPRSS6 on hepcidin expression is underscored by the
observation that patients and mice with mutations in this gene are affected by iron-refractory
iron deficiency anemia (IRIDA) [117]. In Hbbth3/+ mice, use of both antisens oligonucleotide
(Tmprss6-ASO9) and RNA interference (Tmprss6-siRNA) can reduce the synthesis of trans‐
membrane serine protease TMPRSS6 by degrading the corresponding mRNA. This led to
increased hepcidin expression, decreased Tf-sat, and reduction of hemichrome formation and
apoptosis in erythroid cells suggesting that these Tmprss6 inhibitors could be beneficial in
individuals with β-thalassemia [117]. Hepcidin levels can be also altered by targeting a bone
morphogenetic protein-dependent (BMP-dependent) pathway known to be central to the
regulation of hepcidin expression. This pathway involves a multitude of extracellular factors
such as GDF15 and TWSG1. These factors are both BMP antagonists produced by erythroblasts
that inhibit hepcidin expression in vitro, suggesting their role as putative components of the
erythroid regulator [122]. A major goal of hemoglobinopathy research is to develop treatments
that correct the underlying molecular defects responsible for β-thalassemia. One approach to
achieving this goal is the reactivation of γ-globin synthesis by farmacologic induction. Many
of the events controlling the activity of the β-globin locus are known, but the details of those
regulating normal human hemoglobin switching and reactivation of HbF in adult hemato‐
poietic cells remain to be elucidated. Agents that increase human HbF in patients may work
at one or more levels: for example, hydroxyurea and 5-azacytidine kill dividing cells prefer‐
entially and may increase γ-globin expression indirectly through this effect; butyrate may
work both by increasing γ-globin translation on ribosomes and by inhibition of histone
deacetylase (HDAC) [39, 112,123]. It was showed that Stem Cell Factor (SCF) induced an “in
vitro” expansion of effective erythropoiesis and a reactivation of γ-globin synthesis up to fetal
levels, paving the way to its potential use in the therapeutic treatment of this disease [124].
Recently it was reported the ability of thalidomide to increase γ-globin gene expression and
the proportion of HbF-containing cells in a human “in vitro” erythroid differentiation system.
This study has also showed that thalidomide induced production of ROS causing p38 MAPF
phosphorylation and globally increased histone H4 acetylation [125]. However, the mecha‐
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nisms of action of these agents are not yet defined and their role in β-thalassemia therapy is
still being explored in light of its acceptable toxicity profiles adding to their promise as
therapeutic agents. Key genes controlling fetal/adult globin switching have been identified
(e.g. BCL11 and cMYB) and may ultimately serve as direct targets for small molecules that
would increase HbF levels in β-thalassemic patients [126–127]. Finally, the fact that most HbF-
inducing agents are cytotoxic and many activate the p38MAPK cell stress signaling pathway
suggested the importance of what has been termed the “integrated stress response” pathway
in erythroid cells to understanding HbF induction. A variety of stress stimuli activate this
pathway in erythroid cells: viral infection, ROS, heat shock, NO, ultraviolet irradiation,
endoplasmic reticulum stress, inadequate nutrients, proteasome inhibition and limiting
amounts of heme [112].
8. Conclusion
The discovery of hepcidin and its role in iron homeostasis has revolutionized our understand‐
ing of the pathogenesis of iron overload and iron-restricted anemias and has stimulated the
development of new diagnostic and therapeutic methods for these disorders. Several physio‐
logical stimuli regulate the production of the iron-regulatory hormone hepcidin: iron loading,
inflammation, and erythropoiesis. These stimuli modulate iron availability for erythropoiesis
and other physiological processes and regulate the level of body iron stores by altering
hepcidin levels. However, important scientific questions still remain to be answered. Further
work is required to understand the mechanisms of hepcidin regulation by iron and erythroid
activity; to elucidate the structure, the transport function and the complex regulation of the
hepcidin receptor ferroportin; to define the hepcidin role in iron homeostasis. In the coming
years, these efforts are likely to yield new therapeutical approaches for the treatment of anemia
and iron overload disorders.
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